C&R Research KRX:359090KOSDAQ
씨엔알리서치 · Korean news coverage and regulatory filings, organized.
Articles, 24h3
Articles, 7 days3
DART filings, 7 days0
Articles tracked23since Sep 11
In Q2 2026, C&R Research reported revenue of ₩17.8bn, up 5.0% year on year, and operating profit of ₩176m. C&R Research (씨엔알리서치) appeared in 3 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 29 with 3 articles. The most common catalyst was tech & capacity (2). It was most often mentioned alongside 글로벌테크놀로지.
C&R Research quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩17.8bn | +5.0% | ₩176m margin 1.0% | −₩136m |
| Q1 2026 | ₩14.8bn | -13.4% | −₩974m margin −6.6% | −₩1.0bn |
| Q4 2025 derived | ₩15.2bn | +7.1% | ₩93m margin 0.6% | −₩406m |
| Q3 2025 | ₩15.8bn | -4.0% | ₩246m margin 1.6% | ₩547m |
| Q2 2025 | ₩16.9bn | +18.4% | ₩1.3bn margin 7.4% | ₩1.2bn |
| Q1 2025 | ₩17.0bn | +15.7% | −₩215m margin −1.3% | −₩354m |
| Q4 2024 derived | ₩14.2bn | -9.7% | −₩753m margin −5.3% | −₩19m |
| Q3 2024 | ₩16.5bn | +20.6% | ₩2.6bn margin 15.8% | ₩2.0bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
C&R Research top stories 2 weeks, by number of outlets
- 1
- 2
- 3
Latest C&R Research news Korean headlines
-
Major씨엔알리서치·비티시너지, 역노화 마이크로바이옴 개발 협력
1 more on this story · 1 outlets
- 씨엔알리서치·비티시너지, AI 기반 역노화 마이크로바이옴 개발 협력바이오타임즈 · Oct 29 17:28
-
씨엔알리서치, 글로벌 CRO 47위·APAC 15위…아시아 임상 경쟁력 확대
1 more on this story · 1 outlets
- 씨엔알리서치, CareerAidHub CRO 평가 글로벌 47위·APAC 15위뉴스핌 · Oct 8 10:07
-
씨엔알리서치-강남세브란스병원, 의료기기 글로벌 진출 협력
3 more on this story · 3 outlets
- 씨엔알리서치·강남세브란스병원, 의료기기 글로벌 진출 협력더바이오 · Sep 21 08:22
- 씨엔알리서치, 강남세브란스와 혁신 의료기기 글로벌 진출 협력파이낸셜뉴스 · Sep 21 09:04
- 씨엔알리서치, 강남세브란스병원과 의료기기 글로벌 진출 협력…임상 실증 강화바이오타임즈 · Sep 21 11:01